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Abstract 
Background 
The Treatment Satisfaction Questionnaire for Medication (TSQM) was designed to assess 
patient treatment satisfaction in chronic diseases. Its performance has not been examined in 
MS. The 14 items of the TSQM cover 4 domains: Effectiveness; Side Effects; Convenience; 
and Global Satisfaction.  
 
Objective 
To evaluate performance of the TSQM in patients with relapsing MS, using data collected 
from the TENERE study (NCT00883337), in which 324 patients received oral teriflunomide or 
subcutaneous interferon beta-1a for ≥48 weeks. 
 
Methods 
Five measurement properties were examined using traditional psychometric methods: data 
completeness, scale-to-sample targeting, scaling assumptions, reliability (including test-
retest), and construct validity (internal: item-level scaling success, confirmatory factor 
analysis, and exploratory factor analysis; external: convergence, discrimination, and group 
differences). 
 
Results 
There were few (<2%) missing item data; domain scores could be computed for all patients. 
Score distributions were skewed towards higher satisfaction; 2 domains had marked ceiling 
effects. Scaling assumptions were supported. Internal consistency reliability was high 
(Cronbach’s α >0.90). Internal validity tests supported item groupings. Correlations 
supported convergent and discriminant construct validity; hypothesis testing supported 
group differences validity. 
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Conclusion 
This investigation found the TSQM to be a useful tool, exhibiting good psychometric 
measurement properties in patients with relapsing MS in the TENERE study. 
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Introduction 
Patient satisfaction with medication, resulting from factors such as the effectiveness, 
convenience (e.g. route of administration, dosing frequency), or side effects of the 
medication, is associated with better adherence to, and persistence with, treatment.1, 2 
These findings, consistent across many diseases and clinical settings,2 highlight the ongoing 
need to evaluate and improve patients’ treatment experience. 
Many scales have been used to measure treatment satisfaction. Frequently, they are applied 
inconsistently and/or have not been evaluated in the specific disease setting being 
assessed.1 In their roadmap to patient-focused outcome measurement in clinical trials 
(Figure 1), the US Food and Drug Administration highlight the importance of examining 
clinical outcome assessments (COAs) in their context of use.3 This is because COA suitability, 
as a measure of the concept of interest, is dependent upon the context of use. There is, 
therefore, no such thing as a “validated instrument”. EU and US guidelines recommend that, 
if a measurement instrument is applied in a new disease setting, it is confirmed as fit for 
purpose in that context.4, 5 
The Treatment Satisfaction Questionnaire for Medication (TSQM) was designed as a general 
measure of treatment satisfaction with medication. An initial pool of 55 candidate items was 
developed from focus groups of a panel of 500 patients with chronic disease (migraine, 
arthritis, hypertension, asthma, diabetes, psoriasis, hypercholesterolemia, and depression) 
and refined to 31 test items. Via a multistep iterative process, these were reduced to 14 final 
items (Supplementary Appendix 1) covering the majority of the variance in the test 
population.6 
The TSQM has been examined, using standard psychometric methods, in several settings,6, 7 
though not yet in MS. A study using data from 400 patients with cystic fibrosis treated with 
inhaled antibiotics concluded that the TSQM had good measurement properties in patients 
with this condition.7 Using data from patients with various chronic diseases (see above) 
Atkinson and colleagues applied psychometric tests to examine the performance of the 
TSQM, and also concluded that it possessed good psychometric properties.6 Some of their 
findings are noteworthy for patients with MS; they reported significant differences across 
the TSQM between different methods of treatment administration, with individuals using 
injectable therapies reporting low satisfaction and convenience.6 
May 2016 
 
Page 5 
 
In patients with RMS, longer treatment duration has been linked with improved long-term 
outcomes,8 so it is important to ensure patient treatment satisfaction in order to maximize 
persistence with treatment over the long term.2 Teriflunomide, a once-daily oral 
immunomodulator approved for the treatment of relapsing-remitting MS, demonstrated 
consistent efficacy with a well-documented safety profile in randomized, placebo-controlled 
monotherapy studies in patients with relapsing forms of MS (RMS)9-11 and in patients with a 
first clinical episode suggestive of MS.12 The phase 3 TENERE study (NCT00883337) 
compared teriflunomide with subcutaneous interferon beta-1a (scIFNβ-1a) in patients with 
RMS, and included the 14-item TSQM to measure patient satisfaction with either 
intervention.13 The TSQM has been used in many studies of patient satisfaction in MS 
(reviewed by Ting and colleagues14), but to our knowledge, its measurement performance 
has yet to be examined comprehensively in the MS context of use. 
Here, we examine the performance of the TSQM in patients with RMS using traditional 
psychometric methods to determine its fitness for purpose in the TENERE sample of patients 
with RMS. 
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Methods 
Study design and participants 
Details of the TENERE study are published elsewhere.13 Briefly, patients aged 18 years or 
older with a diagnosis of RMS, an Expanded Disability Status Scale (EDSS) score of ≤5.5, and 
no relapse(s) within the prior 30 days were randomized (1:1:1) to receive once-daily 
teriflunomide 14 mg or 7 mg, or scIFNβ-1a 44 μg thrice weekly. The study was designed to 
end 48 weeks after the last patient was randomized.13 Patient satisfaction with treatment 
was assessed using the TSQM version 1.4.13 
TSQM structure 
The TSQM (version 1.4) comprises 14 items across 4 domains focusing on effectiveness (3 
items), side effects (5 items), convenience (3 items), and global satisfaction (3 items) of the 
medication over the previous 2–3 weeks, or since the patient’s last use.6 With the exception 
of item 4 (presence of side effects; yes or no), all items have 5 or 7 responses, scored from 1 
(least satisfied) to 5 or 7 (most satisfied). The 7-item scales had a non-neutral midpoint, such 
that there were more positive response options than negative response options, to allow for 
precise information to be obtained at the upper end of the score distribution. Item scores 
are summed to give 4 domain scores, which are in turn transformed to a scale of 0–100. 
Item 4 was not included for scoring. If an item score is missing and half of the items in the 
domain are complete, domain scores may be imputed from the person-specific mean score 
of completed items.15 
 
TSQM administration 
The TSQM was administered every 12 weeks from Week 12 to Week 48, and every 24 weeks 
thereafter up to Week 96.13 The TSQM was administered in patients’ local languages, 
usingtranslations of the original questionnaire certified by translation agencies as 
linguistically equivalent (Supplementary Appendix 2). 
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TSQM evaluation 
Five TSQM measurement properties were evaluated using TENERE data. Week 48 data were 
used unless otherwise indicated, as Week 48 was the timepoint used for the primary analysis 
of TENERE.13 
Data completeness  
To assess the extent to which the TSQM could be used successfully in TENERE (i.e. how 
acceptable the questionnaire is to test subjects), we computed item-level missing data for 
randomized patients, and the proportions of patients for whom domain scores could be 
computed. Fewer missing data indicate greater acceptability.16 
Scaling assumptions 
We assessed the legitimacy of summing TSQM item scores from TENERE, without weighting 
or standardization, to generate domain scores. Summing is considered legitimate when 
items of a domain are broadly parallel and contribute similarly to the construct being 
measured. These requirements are considered satisfied when items have similar means and 
variances17, and item-to-domain score correlations, corrected for overlap, exceed 0.30.18 
Scale-to-sample targeting 
To examine the match between the potential range measured by the TSQM and the 
observed range measured in TENERE, we examined domain score distributions to ascertain 
the extent to which these met the recommended criteria of: spanning the available scale 
range,19 mean scores located near the scale mid-point,20 not being excessively skewed 
(skewness <1.0),16 and floor and ceiling effects (proportions of patients with minimum and 
maximum scores, respectively) <20%.21 
Reliability 
Multiple reliability indicators are available to evaluate the extent to which scale scores are 
free from random error. We examined internal consistency (corrected item-total 
correlations, Cronbach’s α, and homogeneity coefficients [mean item-item correlations for 
each domain]), test-retest reproducibility (agreement between scores at separate time 
points), and standard errors of measurement. Reliability is considered adequate for group 
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comparisons when corrected item-total correlations are >0.30,22 Cronbach’s α >0.80,23 and 
homogeneity coefficients >0.30.20 
The relatively long measurement interval in TENERE (≥12 weeks) could allow change over 
time to confound interpretation of test-retest estimates. Therefore, a conservative estimate 
of test-retest reproducibility was approximated by comparing TSQM values at Weeks 24 and 
48 for patients with stable disease, defined as patients without relapses for the duration of 
treatment. A random effects model intra-class correlation coefficient was calculated using 
values generated by a repeated measures ANOVA, and a score >0.80 was considered 
acceptable.23 
Standard errors of measurement, computed as standard deviation*√[1-reliability 
coefficient]) were used to interpret reliability estimates as confidence intervals (CIs) around 
scores (95% CI = score ±1.96*standard error of measurement), using Cronbach’s α as the 
reliability coefficient. Low standard errors of measurement demonstrate low measurement 
error.24  
Validity 
To assess the extent to which the TSQM measures the constructs it purports to measure, we 
first tested internal construct validity (the extent to which items of the TSQM are grouped 
correctly into domains) as a prerequisite for interpretation of external construct validity 
tests (which provide more direct information on the constructs measured). Three 
examinations of internal construct validity were undertaken. Item-level convergent and 
discriminant validity was tested by computing scaling success rates. A definite scaling 
success was scored when an item’s correlation with its own domain (corrected for overlap) 
was significantly higher (>2*standard error) than its correlations with another domain. 
Exploratory factor analysis [EFA], performed as a maximum likelihood factor analysis, was 
used to identify factors that explain the maximum amount of variance. Confirmatory factor 
analysis [CFA] was performed as an hypothesis-driven approach to further understand 
shared variance between variables due to factors. Goodness-of-fit indices were assessed 
against predefined criteria for good fit: Root Mean Square Error of Approximation <0.08, 
Normed Fit Index >0.9, Goodness of Fit Index >0.9, Adjusted Goodness of Fit Index >0.9, and 
standardized Root Mean Square Residual <0.05. 
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Two examinations of external construct validity of the TSQM were undertaken. Firstly, scale-
level convergent and discriminant construct validity was tested by examining the extent to 
which the direction, magnitude, and pattern of correlations between variables were 
consistent with expectation. We examined correlations between TSQM domains and 
baseline patient characteristics (age, gender, EDSS, and Fatigue Impact Scale [FIS] scores), 
hypothesizing that that these correlations would be lower than the TSQM between-domain 
correlations. Secondly, group differences construct validity was tested using score 
differences between responders and non-responders on a range of clinical outcomes. The 
outcomes were selected based on measured parameters that we hypothesized would be 
likely to explain a clinical difference, and are detailed in Supplementary Table 1. Group 
mean score differences were expressed in terms of statistical (p value from independent 
samples analysis of variance [ANOVA]) and clinical significance (Cohen’s d; effect size, ES). ES 
was interpreted using Cohen’s criteria: ≥0.2–<0.5 for a small difference; ≥0.5–≤0.8 for a 
moderate difference; and >0.8 for a large difference.25 
Results 
Study participants 
Patient characteristics in the TENERE study (Table 1) 13 were generally similar to those of 
patients in other Phase 3 studies of teriflunomide9, 10 and other oral disease-modifying 
treatments for RMS,26-29 albeit with a slightly lower mean EDSS score at baseline in TENERE. 
Data completeness 
TSQM data completeness in TENERE was good. Each item was missing a response in fewer 
than 2% of patients (n=324; range: 0.3–1.9%; Table 2). Domain scores could be computed 
for all participants (Supplementary Table 2). 
Scaling assumptions 
Scaling assumptions were satisfied for all 4 domains. Item mean scores and variances were 
similar (Supplementary Table 2) and all item total correlations (corrected for overlap) 
exceeded 0.30 (Table 2). This supports, for each domain, the summing of item scores to 
generate domain scores without standardization or weighting. 
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Scale-to-sample targeting 
For all domains except Effectiveness, scores did not span the whole scale range, 
demonstrating skewing towards high scores (Table 2). Mean and median scores exceeded 
the scale midpoint (50). High mean scores accompanied by ceiling effects (defined as 
maximum scores in >20% of patients) were particularly marked for Side Effects (mean score 
90.1, 72% of patients with maximum score), and Convenience (mean score 82.2, 38% of 
patients with maximum score). Both domains had notable higher ceiling effects with oral 
treatment (teriflunomide) than with injectable treatment (scIFNβ-1a). There were no 
notable floor effects, with small percentages of patients with minimum scores (minimal 
satisfaction) in each domain. Together, these high scores suggest good overall treatment 
satisfaction that was generally higher with teriflunomide than with scIFNβ-1a.13, 30  
Reliability 
Internal consistency reliability was high for all domains, with Cronbach’s α >0.90 and all 
homogeneity coefficients >0.75; corresponding standard errors of measurement were thus 
relatively small. Test-retest reproducibility coefficients exceeded 0.70 for three domains 
(Side Effects, Convenience, Global Satisfaction) indicating adequate reproducibility given 
that these were likely conservative etimates.23 The coefficient for Effectiveness was low 
(0.44). 
Validity 
Tests of internal construct validity supported the proposed item groupings. Definite scaling 
success rates for all 4 domains were 100% (Table 2). EFA grouped the 13 scoring items into 4 
factors with item content equivalent to the 4 TSQM domains (Supplementary Table 3). CFA 
(Figure 2) also supported TSQM item groupings; at Week 48, Goodness of Fit indices met the 
predefined criteria. The largest contribution to Global Satisfaction came from Effectiveness 
(standardized estimate for association was 0.63), followed by Convenience (0.54) and Side 
Effects (0.32). 
Tests of external construct validity supported the constructs measured by the domains. 
Correlations among TSQM domains were consistent with expectation, and supported the 4 
domains as measures of related but different constructs (Supplementary Table 2). As in the 
CFA, perceived effectiveness was linked with Global Satisfaction (correlation coefficient, 
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0.69). Correlations between TSQM domains and age, gender, EDSS, and FIS were low 
(ranging from 0.01 to -0.31), indicating treatment satisfaction was not biased by these 
variables (Supplementary Table 2). 
As hypothesized, there was a statistically significant (p≤0.05) and clinically meaningful 
(ES >0.3) relationship between each TSQM domain and the clinical outcomes tested (Table 
3). For example, the minimal number of patients with adverse events leading to treatment 
discontinuation had a statistically (p<0.0001) and clinically (ES, 3.24) significantly (reduced 
Side Effects domain score (31.3; n=2) compared with patients who did not (90.6; n=243). 
There were also highly statistically significant (p<0.0001) relationships between the 
Convenience domain and relevant clinical outcomes. Treatment received 
(teriflunomide/scIFNβ-1a, used as a proxy for mode of administration) showed the strongest 
relationship (ES=1.74) with Convenience. 
Discussion 
This analysis provided a comprehensive evaluation, using traditional psychometric methods, 
of the extent to which the 14-item version of the TSQM is a fit-for-purpose measure of 
treatment satisfaction in the TENERE study of patients with RMS. Overall, we found that the 
TSQM exhibits good measurement properties and met the requirements of traditional 
psychometric tests. Specifically, we found that item scores could be summed without 
weighting or standardization to form total scores that were reliable, and for which evidence 
supported their validity as measures of different aspects of treatment satisfaction. 
Analysis of scale-to-sample targeting identified a potential limitation of the TSQM for the 
relapsing MS context of use. Marked ceiling effects for the Side Effects and Convenience 
domains were observed in the teriflunomide-treated group. This may be a reflection of high 
levels of patient satisfaction with teriflunomide treatment, which is supported by the 
significant and clinically meaningful improvement in TSQM score for the teriflunomide 14-
mg group versus the scIFNβ-1a 44-μg group on the Side Effects and Convenience domains in 
TENERE.13, 30 Preliminary results from the Teri-PRO (Teriflunomide Patient-Reported 
Outcomes; NCT01895335) study of real-world teriflunomide use also indicate that patient 
satisfaction, as measured by the TSQM, increases when patients switch their disease-
modifying therapy to teriflunomide.31 Furthermore, an analysis of the TSQM in patients with 
chronic diseases found that injectable modes of administration were associated with lower 
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TSQM scores, which could again suggest that scores for teriflunomide-treated patients are 
expected to be higher than those of patients treated with scIFNβ-1a.6 The skewed mean 
scores and high ceiling effects we observed may indicate that the TSQM limited the possible 
measurement of satisfaction in these patients, with the “true” satisfaction of the 
teriflunomide-treatment group likely to be higher than that actually measured; the 
differences between scIFNβ-1a and teriflunomide may, therefore, be larger than measured. 
In this analysis, internal consistency indicators (Cronbach’s α and homogeneity coefficients) 
were very high, particularly given the small numbers of items in each domain. This implies 
the items in each domain were closely related and may suggest possible item redundancy.32 
However, indicators of internal consistency may also be elevated spuriously by ceiling or 
floor effects, and we have noted skewed score distributions in our analysis. Reanalysis of 
reliability could help to determine if there is true item redundancy. Though traditional 
psychometric methods are widely used, they do have recognized limitations.33 In this 
instance, reliability analyses using the person separation index generated by the more 
modern Rasch measurement theory analysis,34 might be informative. 
Though the intervals between TSQM data collection were too long to permit a robust 
evaluation of test-retest reproducibility, our conservative approximations implied that high 
reproducibility is to be expected for 3 domains (Global Satisfaction, Convenience, Side 
Effects). It is difficult to know how best to interpret the value of 0.44 for Effectiveness, and 
this merits further investigation. 
CFA implied that Global Satisfaction with treatment within the TENERE study population was 
driven primarily by Effectiveness, followed by Convenience and Side Effects. This is 
consistent with studies of treatment adherence in patients with MS, which have identified 
treatment efficacy as important and lack of efficacy as a key reason for treatment 
discontinuation,35, 36 and also with findings in other diseases, which showed Global 
Satisfaction was most strongly linked with Effectiveness.6 It would be of interest to explore 
how relapses and disability progression are linked with changes in TSQM, and if these clinical 
changes in turn affect its measurement properties. 
Though the patient-unblinded nature of TENERE may have influenced patient satisfaction 
ratings,13 we do not expect it to influence the empirical measurement performance of the 
TSQM, as analyzed in this study. 
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An important next step would be to examine the item content of the TSQM, to optimize it 
for the RMS patient population. Qualitative research might identify new items that extend 
the measurement range of the TSQM, reduce ceiling effects, and advance measurement of 
treatment satisfaction in patients with RMS. 
To our knowledge, this is the first time the performance of the TSQM has been evaluated in 
a sample of patients with RMS. While, as noted, evaluation in a single study population does 
not confirm measurement performance in all contexts, our comprehensive analysis supports 
the TSQM as a fit-for purpose measure of treatment satisfaction in TENERE. Based on this, it 
seems reasonable to conclude that TSQM is likely to be appropriate for use in studies of 
disease-modifying therapies for patients with RMS. Indeed, the tool is being used as an 
outcome measure to provide further understanding of patient experiences of teriflunomide 
treatment in routine clinical practice in ongoing phase 4 studies,31 and it is our intention to 
use data from such studies to perform a follow-on evaluation of TSQM performance in the 
context of use of real-world patients with RMS. However, as with all instruments, detailed 
analysis demonstrates room for improvement. Here, the suboptimal scale-to-sample 
targeting implies that treatment satisfaction maybe underestimated by the TSQM in this 
context of use, and modification of the TSQM may overcome this limitation. 
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Tables and Figures 
Table 1. Baseline demographics and disease characteristics. 
  sc IFN β-1a  
(n=104) 
Teriflunomide 
7 mg  
(n=109) 
Teriflunomide 
14 mg 
(n=111) 
Age, years¸ mean (SD) 37.0 (10.6) 35.2 (9.2) 36.8 (10.3) 
Female, n (%) 71 (68.3) 70 (64.2) 78 (70.3) 
Caucasian, n (%) 104 (100) 109 (100) 111 (100) 
Time since first symptoms of 
MS, years, mean (SD) 
7.7 (7.6) 7.0 (6.9) 6.6 (7.6) 
No. of relapses within 
previous year, mean (SD) 
1.2 (1.0) 1.3 (0.8) 1.4 (0.8) 
Relapsing–remitting MS, 
n (%) 
104 (100) 109 (100) 108 (97.3)a 
Use of DMT in previous 
2 years, n (%) 
25 (24.0) 23 (21.1) 13 (11.7) 
Baseline EDSS score, mean 
(SD) 
2.0 (1.2) 2.0 (1.2) 2.3 (1.4) 
Baseline FIS score, mean (SD) 34.2 (32.7) 39.5 (34.8) 42.5 (37.8) 
Randomized population, n=324. 
aSecondary progressive MS, n=1; progressive relapsing MS, n=2. 
DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; FIS: Fatigue Impact 
Scale; IFN: interferon; sc: subcutaneous; SD: standard deviation. 
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Table 2. Item-level analyses of TSQM. 
Domain Item 
Response 
categories, 
n 
Patients with 
missing data, 
n (%)a 
Correlation with domainb,c 
Scaling 
success 
rate, %d 
Effect-
iveness 
Side 
Effects 
Conven-
ience 
Global 
Satis-
faction 
Effect-
iveness 
Q1 Satisfaction with prevention/treatment 7 3 (0.9) 0.90 0.19 0.27 0.54 
100 Q2 Satisfaction with symptom relief 7 5 (1.5) 0.88 0.24 0.27 0.56 
Q3 Satisfaction with time to start working 7 5 (1.5) 0.89 0.21 0.31 0.56 
Side 
Effects 
Q4 Side effect presencee 2 6 (1.9) NA NA NA NA 
100 
Q5 Bother from side effects 5 4 (1.2) 0.19 0.76 0.44 0.26 
Q6 
Side effects interference with physical 
function 
5 4 (1.2) 0.25 0.83 0.46 0.26 
Q7 
Side effects interference with mental 
function 
5 2 (0.6) 0.23 0.66 0.42 0.29 
Q8 Impact of side effects on satisfaction 5 2 (0.6) 0.23 0.71 0.50 0.34 
Conven-
ience 
Q9 Treatment easy to use 7 1 (0.3) 0.24 0.44 0.83 0.39 
100 Q10 Easy planning of use 7 1 (0.3) 0.23 0.42 0.82 0.41 
Q11 Intake convenience 7 2 (0.6) 0.36 0.41 0.82 0.52 
Global 
Satis-
faction 
Q12 Confidence in benefits 5 2 (0.6) 0.51 0.19 0.36 0.81 
100 Q13 Balance between good and bad things 5 2 (0.6) 0.49 0.23 0.38 0.83 
Q14 Global satisfaction 7 3 (0.9) 0.59 0.33 0.55 0.80 
aRandomized population, n=324; bPatients from intent-to-treat population with complete TSQM domain information at Week 48, n=243–246; cItem-own 
domain correlations corrected for item overlap (bold); dPercentage of correlations where item-own domain correlation (corrected for overlap) exceeds item 
–other domain correlation by more than 2*SE (where SE = 1/√n); eDichotomous item, not scored.  
NA: not applicable; SE: standard error; TSQM: Treatment Satisfaction Questionnaire for Medication (version 1.4).6 
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Table 3. Relationships between clinical outcomes and TSQM domains at Week 48. 
Domain Clinical outcome 
Patients with outcome Patients without outcome Effect size, 
Cohen’s d 
p valuea 
n Score, mean (SD) n Score, mean (SD) 
Effectiveness Treatment failureb 51 61.2 (19.5) 192 68.8 (22.4) 0.35 0.028 
Confirmed relapse 50 61.6 (19.6) 193 68.7 (22.4) 0.33 0.041 
Side Effects AEs leading to treatment 
discontinuation 
2 31.3 (17.7) 243 90.6 (18.3) 3.24 0.020 
Nervous system disorders 92 86.1 (21.5) 153 92.6 (17.0) 0.38 0.009 
General disorders or 
administration-site conditionsc 
73 82.0 (24.6) 172 93.6 (15.0) 0.63 <0.0001 
Convenience Treated with sc IFN β-1ad 74 63.2 (19.1) 176 89.8 (13.4) 1.74 <0.0001 
General disorders or 
administration-site conditionsc 
74 74.0 (22.1) 172 85.8 (17.0) 0.63 <0.0001 
Global 
Satisfaction 
Treatment failureb 52 63.2 (21.2) 193 72.2 (20.7) 0.43 0.006 
Confirmed relapse 51 63.6 (21.3) 194 72.1 (20.8) 0.41 0.011 
Table shows all relationships with p<0.05 for patients with complete TSQM domain information at Week 48; aP value from ANOVA; bConfirmed relapse or 
permanent treatment discontinuation for any reason; cGeneral disorders and administration-site conditions were mainly driven by influenza-like illness; 
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dSpecific outcomes for convenience are difficult to identify in a randomized controlled trial, and we observed a relationship with AEs related to mode of 
administration (injectable sc IFN β-1a vs oral teriflunomide) using treatment received as a proxy. 
AE: adverse event; ANOVA: analysis of variance; IFN: interferon; sc: subcutaneous; SD: standard deviation; TSQM: Treatment Satisfaction Questionnaire for 
Medication (version 1.4). 6 
 
May 2016 
 
Page 23 
 
Supplementary Table 1. Testing performed on relationships between clinical outcomes and TSQM domains. 
Domain Clinical outcome Rationale for choice Hypothesis tested 
Effectiveness  
and Global 
Satisfaction 
Treatment failure  
Confirmed relapse or permanent 
treatment discontinuation for any 
reason 
Primary study endpoint As clinical efficacy has been demonstrated 
for both teriflunomide and IFN β,9, 10, 37 as 
both Effectiveness and Global Satisfaction 
improve following initiation of teriflunomide 
treatment,31 and as the clinical effectiveness 
of a treatment has been linked to treatment 
satisfaction,38 we hypothesize that these sets 
of measures would be linked 
Confirmed relapse A commonly used efficacy measure in 
studies of DMTs in RMS (other efficacy 
measures such as disability or MRI 
outcomes were not recorded in TENERE) 
Side Effects AEs leading to treatment 
discontinuation 
To be representative of the relationship 
between AEs and treatment satisfaction 
Since tolerability is linked with patient 
treatment satisfaction,38 we would expect to 
see a relationship between the Side Effects 
domain, and these AE parameters as a 
clinical outcome 
Nervous system disorders The AEs with the highest incidence in this 
study General disorders or administration-
site conditions 
Convenience Treated with sc IFN β-1a  
Proxy for mode of administration 
(injection vs oral) 
Convenience has been shown to be 
linked to mode of administration,6 and 
specific outcomes for convenience are 
hard to identify in a randomized 
controlled trial 
We hypothesize that the improved 
convenience with teriflunomide vs IFN β 
seen in TENERE,30 may be explained by the 
differing modes of administration General disorders or administration-
site conditions 
AE: adverse event; DMT: disease-modifying therapy; IFN: interferon; RMS: relapsing forms of MS; sc: subcutaneous; TSQM: Treatment Satisfaction 
Questionnaire for Medication (version 1.4). 
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Supplementary Table 2. Domain-level analyses of TSQM. 
Variable 
TSQM domain 
Effectiveness Side Effects Convenience Global Satisfaction 
 
k 3 5 3 3 
n 243 245 246 245 
Scaling assumptions 
Item mean range 4.95–5.10 4.49–4.67 5.83–6.00 3.69–5.43 
Item SD range 1.34–1.43 0.69–0.94 1.16–1.33 1.01–1.19 
Item total correlation rangea 0.74–0.96 0.69–0.80 0.72–0.83 0.75–0.86 
Scale-to-sample targetingb 
Mean (SD) 67.2 (22.0) 90.1 (19.1) 82.2 (19.4) 70.3 (21.1) 
Median (range) 66.7 (0–100) 100 (18.8–100) 83.3 (11.1–100) 71.4 (14.3–100) 
Floor effects, n/N (%) 
All patients 4/243 (1.65) 4/245 (1.63) 1/246 (0.41) 1/245 (0.41) 
sc IFN β-1a 44 μg 1/69 (1.45) 4/69 (5.80) 1/70 (1.43) 1/70 (1.43)  
Teriflunomidec  3/174 (1.72) 0d/176  0d/176 0d/175 
Ceiling effects, n/N (%) 
All patients 25/243 (10.3) 176/245 (71.8) 94/246 (38.2) 39/246 (15.9) 
sc IFN β-1a 44 μg 5/69 (7.25)  26/69 (37.7) 4/70 (5.71) 22/175 (12.6) 
Teriflunomidec 20/174 (11.5)  150/176 (85.2) 90/176 (51.1) 7/70 (10.0) 
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Reliability 
Cronbach’s α  0.95 0.94 0.91 0.91 
Homogeneity coefficient 0.82 0.76 0.77 0.79 
Standard error of measurement 4.92 4.68 1.75 6.33 
Test-retest reliabilitye  0.44 0.72 0.82 0.81 
Validity 
Within-scale correlations 
Effectiveness 1 0.25 0.42 0.69 
Side Effects  1 0.48 0.42 
Convenience   1 0.46 
Global Satisfaction    1 
Correlations between TSQM domainsf and other variables 
Age at baseline -0.15 -0.05 0.01 -0.10 
Genderg -0.058 -0.157 0.007 -0.072 
EDSS score at Week 12 -0.19 -0.05 -0.02 -0.15 
FIS score at Week 12 -0.23 -0.31 -0.11 -0.17 
Patients from intent-to-treat population with complete TSQM domain information at Week 48. aCorrected for item overlap; bScores are transformed to give 
a range of 0–100; c14-mg and 7-mg dose groups combined; dNo floor effect, for lowest score see range, above. Floor score (lowest patient satisfaction) = 0, 
ceiling score (greatest patient satisfaction) = 100; eIntra-class correlation coefficient between scores at Week 24 and Week 48 in patients without relapses; 
fAt Week 12, Pearson correlations; gBiserial correlation. 
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EDSS: Expanded Disability Status Scale; FIS: Fatigue Impact Scale; IFN: interferon; sc: subcutaneous; SD: standard deviation; TSQM: Treatment Satisfaction 
Questionnaire for Medication (version 1.4).6
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Supplementary Table 3. Exploratory factor analysis: rotated factor pattern by TSQM item. 
TSQM item 
Rotated factor pattern 
Factor 1 Factor 2 Factor 3 Factor 4 
Q1 Satisfaction with 
prevention/treatment 
0.074 0.907 0.110 0.235 
Q2 Satisfaction with symptom 
relief 
0.133 0.847 0.084 0.280 
Q3 Satisfaction with time to start 
working 
0.097 0.860 0.144 0.259 
Q5 Bother from side effects 0.913 0.061 0.186 0.090 
Q6 Side effects interference with 
physical function 
0.918 0.132 0.222 0.050 
Q7 Side effects interference with 
mental function 
0.795 0.107 0.189 0.103 
Q8 Impact of side effects on 
satisfaction 
0.839 0.084 0.258 0.158 
Q9 Treatment easy to use 0.261 0.094 0.844 0.138 
Q10 Easy planning of use 0.251 0.076 0.824 0.170 
Q11 Intake convenience 0.219 0.189 0.814 0.252 
Q12 Confidence in benefits 0.069 0.301 0.159 0.795 
Q13 Balance between good and bad 
things 
0.118 0.257 0.173 0.836 
Q14 Global satisfaction 0.184 0.370 0.343 0.705 
Factor coincides with TSQM domain 
Side 
Effects 
Effectiven
ess 
Convenien
ce 
Global 
Satisfactio
n 
Homogeneity coefficient 0.87 0.87 0.83 0.78 
TSQM: Treatment Satisfaction Questionnaire for Medication (version 1.4). 
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Figure 1. FDA roadmap to patient-focused outcome measurement in clinical trials.3. 
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Figure 2. Confirmatory factor analysis of the TSQM. 
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Figure Legends 
Figure 1. FDA roadmap to patient-focused outcome measurement in clinical trials.3 
Reproduced by permission of the US Food and Drug Administration. 
Figure 2. Confirmatory factor analysis of the TSQM. 
Ovoids represent unobserved variables (domains); rectangles represent observed variables 
(items); arrows represent the hypothesized links between the variables; parameters relative 
to each arrow are standardized estimates of the strength of association between the linked 
variables.  
Root Mean Square Error of Approximation, 0.067; Normed Fit Index, 0.958; Goodness of Fit 
Index, 0.925; Adjusted Goodness of Fit Index, 0.884; Standardized Root Mean Square 
Residual, 0.044.  
TSQM: Treatment Satisfaction Questionnaire for Medication (version 1.4).6 
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Supplemental Materials 
Appendix 1  
TSQM (Version 1.4) 
Treatment Satisfaction Questionnaire for Medication 
Instructions: Please take some time to think about your level of satisfaction or 
dissatisfaction with the medication you are taking in the clinical trial. We are 
interested in your evaluation of the effectiveness, side effects, and convenience of 
the medication over the last two to three weeks, or since you last used it. For each 
question, please place a single check mark next to the response that most closely 
corresponds to your own experience. 
1. How satisfied or dissatisfied are you with the ability of the medication to prevent or treat 
your condition? 
  1 Extremely Dissatisfied 
   
  2 Very Dissatisfied 
   
  3 Dissatisfied 
   
  4 Somewhat Satisfied 
   
  5 Satisfied 
   
  6 Very Satisfied 
   
  7 Extremely Satisfied 
   
2. How satisfied or dissatisfied are you with the way the medication relieves your 
symptoms? 
  1 Extremely Dissatisfied 
   
  2 Very Dissatisfied 
   
  3 Dissatisfied 
   
  4 Somewhat Satisfied 
   
  5 Satisfied 
   
  6 Very Satisfied 
   
  7 Extremely Satisfied 
   
3. How satisfied or dissatisfied are you with the amount of time the medication takes to 
start working? 
  1 Extremely Dissatisfied 
   
  2 Very Dissatisfied 
   
  3 Dissatisfied 
   
  4 Somewhat Satisfied 
   
  5 Satisfied 
   
  6 Very Satisfied 
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  7 Extremely Satisfied 
   
4. As a result of taking this medication, do you experience any side effects at all? 
  Yes 
   
  No (if No, then please skip to Question 9) 
   
5. How bothersome are the side effects of the medication you take to treat your condition? 
  1 Extremely Bothersome 
   
  2 Very Bothersome 
   
  3 Somewhat Bothersome 
   
  4 A Little Bothersome 
   
  5 Not at All Bothersome 
   
 
6. To what extent do the side effects interfere with your physical health and ability to 
function  
(i.e., strength, energy levels etc.)? 
  1 A Great Deal 
   
  2 Quite a Bit 
   
  3 Somewhat  
   
  4 Minimally 
   
  5 Not at All  
   
7. To what extent do the side effects interfere with your mental function  
(i.e., ability to think clearly, stay awake etc.)? 
  1 A Great Deal 
   
  2 Quite a Bit 
   
  3 Somewhat  
   
  4 Minimally 
   
  5 Not at All  
   
8. To what degree have medication side effects affected your overall satisfaction with the 
medication? 
  1 A Great Deal 
   
  2 Quite a Bit 
   
  3 Somewhat  
   
  4 Minimally 
   
  5 Not at All  
   
9. How easy or difficult is it to use the medication in its current form? 
  1 Extremely Difficult 
   
  2 Very Difficult 
   
  3 Difficult 
   
  4 Somewhat Difficult 
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  5 Easy 
   
  6 Very Easy 
   
  7 Extremely Easy 
   
10. How easy or difficult is it to plan when you will use the medication each time? 
  1 Extremely Difficult 
   
  2 Very Difficult 
   
  3 Difficult 
   
  4 Somewhat Difficult 
   
  5 Easy 
   
  6 Very Easy 
   
  7 Extremely Easy 
   
11. How convenient or inconvenient is it to take the medication as instructed? 
  1 Extremely Inconvenient 
   
  2 Very Inconvenient 
   
  3 Inconvenient 
   
  4 Somewhat Convenient 
   
  5 Convenient 
   
  6 Very Convenient 
   
  7 Extremely Convenient 
   
12. Overall, how confident are you that taking this medication is a good thing for you? 
  1 Not at All Confident 
   
  2 A Little Confident 
   
  3 Somewhat Confident 
   
  4 Very Confident 
   
  5 Extremely Confident 
   
13. How certain are you that the good things about your medication outweigh the bad 
things? 
  1 Not at All Certain 
   
  2 A Little Certain 
   
  3 Somewhat Certain 
   
  4 Very Certain 
   
  5 Extremely Certain 
   
14. Taking all things into account, how satisfied or dissatisfied are you with this medication? 
  1 Extremely Dissatisfied 
   
  2 Very Dissatisfied 
   
  3 Dissatisfied 
   
  4 Somewhat Satisfied 
   
  5 Satisfied 
   
  6 Very Satisfied 
   
  7 Extremely Satisfied 
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Appendix 2 
Certified translations of the TSQM were provided as follows: 
MAPI Institute 
Arabic 
English for the United States 
French 
Greek 
Portugese 
 
Oxford Outcomes Ltd 
Afrikaans 
Armenian 
Austrian German 
Belgian Dutch 
Belgian French 
Bulgarian 
Canadian English 
Canadian French 
Chilean Spanish 
Chinese for Malaysia 
Chinese for Singapore 
Chinese for Taiwan 
Colombian Spanish 
Croatian 
Czech 
Danish 
Dutch 
English for Australia and the UK 
English for India 
English for Malaysia 
English for New Zealand 
English for Singapore 
English for South Africa 
English for the Philippines 
Finnish 
French 
German 
Georgian 
Hebrew 
Hindi 
Hungarian 
Italian 
Kannada 
Korean 
Malay 
Malayalam 
Marathi 
Polish 
Romanian 
Russian 
Slovakian 
Slovenian 
Spanish 
Swedish 
Swiss French 
Swiss German 
Tamil 
Telugu 
Thai 
Turkish 
Ukrainian 
